Stroke - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Stroke - Pipeline Review, H2 2018’, provides an overview of the Stroke pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Stroke, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Stroke and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Stroke

- The report reviews pipeline therapeutics for Stroke by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Stroke therapeutics and enlists all their major and minor projects

- The report assesses Stroke therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Stroke

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Stroke

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Stroke pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Acorda Therapeutics Inc

Acticor Biotech SAS

Addex Therapeutics Ltd

Affibody AB

Amarantus Bioscience Holdings Inc

Anavex Life Sciences Corp

Antoxis Ltd

Apellis Pharmaceuticals Inc

AptaTargets ...

Acorda Therapeutics Inc

Acticor Biotech SAS

Addex Therapeutics Ltd

Affibody AB

Amarantus Bioscience Holdings Inc

Anavex Life Sciences Corp

Antoxis Ltd

Apellis Pharmaceuticals Inc

AptaTargets SL

ArmaGen Inc

Artelo Biosciences Inc

ArunA Biomedical Inc

AstraZeneca Plc

Athersys Inc

BioAxone BioSciences Inc

Biogen Inc

BioTime Inc

Boehringer Ingelheim GmbH

Cardax Inc

Celltrion Inc

CHA Bio & Diostech Co Ltd

CohBar Inc

Daiichi Sankyo Co Ltd

DiaMedica Therapeutics Inc

Diffusion Pharmaceuticals Inc

Epigen Biosciences Inc

Evgen Pharma Plc

F. Hoffmann-La Roche Ltd

Fina Biotech SL

Freeox Biotech SL

GC Pharma

Genervon Biopharmaceuticals LLC

Glialogix Inc

Glucox Biotech AB

Immunwork Inc

Instituto Biomar SA

International Stem Cell Corp

Jeil Pharmaceutical Co Ltd

JT Pharmaceuticals Inc

Les Laboratoires Servier SAS

Living Cell Technologies Ltd

Lixte Biotechnology Holdings Inc

Lumosa Therapeutics Co Ltd

M et P Pharma AG

Mapreg SAS

Meridigen Biotech Co Ltd

Neuralstem Inc

Neuren Pharmaceuticals Ltd

Neurofx Inc

NeuroNascent Inc

NeurOp Inc

New World Laboratories Inc

Nipro Corp

NoNO Inc

Novartis AG

NuvOx Pharma LLC

Nyrada Inc

Pharmagenesis Inc

Pharmicell Co Ltd

Phoenix Biotechnology Inc

PhytoHealth Corp

Prolong Pharmaceuticals LLC

Regeneron Pharmaceuticals Inc

RegeneRx Biopharmaceuticals Inc

ReNetX Bio

ReNeuron Group Plc

Reven Pharmaceuticals Inc

Rich Pharmaceuticals Inc

Rubicon Biotechnology Inc

Saneron CCEL Therapeutics Inc

Saniona AB

Savara Inc

Shin Poong PharmCo Ltd

Shionogi & Co Ltd

Simcere Pharmaceutical Group

Stemedica Cell Technologies Inc

SynZyme Technologies LLC

TaiGen Biotechnology Co Ltd

Tasly Pharmaceutical Group Co Ltd

Tenax Therapeutics Inc

The Cell-Factory BVBA

Thrombolytic Science International LLC

TikoMed AB

Toyama Chemical Co Ltd

Vect-Horus SAS

Verseon Corp

Vicore Pharma AB

Virogenomics BioDevelopment Inc

WhanIn Pharmaceutical Co Ltd

Zensun (Shanghai) Sci & Tech Co Ltd

Zocere Inc

ZZ Biotech LLC

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Stroke – Overview 8

Stroke – Therapeutics Development 9

Stroke – Therapeutics Assessment 34

Stroke – ...

Table of Contents

Table of Contents 2

Introduction 7

Stroke – Overview 8

Stroke – Therapeutics Development 9

Stroke – Therapeutics Assessment 34

Stroke – Companies Involved in Therapeutics Development 50

Stroke – Drug Profiles 91

Stroke – Dormant Projects 495

Stroke – Discontinued Products 508

Stroke – Product Development Milestones 511

Appendix 522

List of Tables

List of Tables

Number of Products under Development for Stroke, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Tables

Number of Products under Development for Stroke, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Stroke – Pipeline by Acorda Therapeutics Inc, H2 2018

Stroke – Pipeline by Acticor Biotech SAS, H2 2018

Stroke – Pipeline by Addex Therapeutics Ltd, H2 2018

Stroke – Pipeline by Affibody AB, H2 2018

Stroke – Pipeline by Amarantus Bioscience Holdings Inc, H2 2018

Stroke – Pipeline by Anavex Life Sciences Corp, H2 2018

Stroke – Pipeline by Antoxis Ltd, H2 2018

Stroke – Pipeline by Apellis Pharmaceuticals Inc, H2 2018

Stroke – Pipeline by AptaTargets SL, H2 2018

Stroke – Pipeline by ArmaGen Inc, H2 2018

Stroke – Pipeline by Artelo Biosciences Inc, H2 2018

Stroke – Pipeline by ArunA Biomedical Inc, H2 2018

Stroke – Pipeline by AstraZeneca Plc, H2 2018

Stroke – Pipeline by Athersys Inc, H2 2018

Stroke – Pipeline by BioAxone BioSciences Inc, H2 2018

Stroke – Pipeline by Biogen Inc, H2 2018

Stroke – Pipeline by BioTime Inc, H2 2018

Stroke – Pipeline by Boehringer Ingelheim GmbH, H2 2018

Stroke – Pipeline by Cardax Inc, H2 2018

Stroke – Pipeline by Celltrion Inc, H2 2018

Stroke – Pipeline by CHA Bio & Diostech Co Ltd, H2 2018

Stroke – Pipeline by CohBar Inc, H2 2018

Stroke – Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Stroke – Pipeline by DiaMedica Therapeutics Inc, H2 2018

Stroke – Pipeline by Diffusion Pharmaceuticals Inc, H2 2018

Stroke – Pipeline by Epigen Biosciences Inc, H2 2018

Stroke – Pipeline by Evgen Pharma Plc, H2 2018

Stroke – Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Stroke – Pipeline by Fina Biotech SL, H2 2018

Stroke – Pipeline by Freeox Biotech SL, H2 2018

Stroke – Pipeline by GC Pharma, H2 2018

Stroke – Pipeline by Genervon Biopharmaceuticals LLC, H2 2018

Stroke – Pipeline by Glialogix Inc, H2 2018

Stroke – Pipeline by Glucox Biotech AB, H2 2018

Stroke – Pipeline by Immunwork Inc, H2 2018

Stroke – Pipeline by Instituto Biomar SA, H2 2018

Stroke – Pipeline by International Stem Cell Corp, H2 2018

Stroke – Pipeline by Jeil Pharmaceutical Co Ltd, H2 2018

Stroke – Pipeline by JT Pharmaceuticals Inc, H2 2018

Stroke – Pipeline by Les Laboratoires Servier SAS, H2 2018

Stroke – Pipeline by Living Cell Technologies Ltd, H2 2018

Stroke – Pipeline by Lixte Biotechnology Holdings Inc, H2 2018

Stroke – Pipeline by Lumosa Therapeutics Co Ltd, H2 2018

Stroke – Pipeline by M et P Pharma AG, H2 2018

Stroke – Pipeline by Mapreg SAS, H2 2018

Stroke – Pipeline by Meridigen Biotech Co Ltd, H2 2018

Stroke – Pipeline by Neuralstem Inc, H2 2018

Stroke – Pipeline by Neuren Pharmaceuticals Ltd, H2 2018

Stroke – Pipeline by Neurofx Inc, H2 2018

Stroke – Pipeline by NeuroNascent Inc, H2 2018

Stroke – Pipeline by NeurOp Inc, H2 2018

Stroke – Pipeline by New World Laboratories Inc, H2 2018

Stroke – Pipeline by Nipro Corp, H2 2018

Stroke – Pipeline by NoNO Inc, H2 2018

List of Figures

List of Figures

Number of Products under Development for Stroke, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under ...

List of Figures

Number of Products under Development for Stroke, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Top 10 Routes of Administration, H2 2018

Number of Products by Stage and Top 10 Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports